Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2019.05.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reslizumab in an invasively ventilated patient with acute respiratory failure.
J Allergy Clin Immunol Pract
October 2020
Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria.
[Bronchial thermoplasty for asthma treatment].
Tuberk Toraks
June 2018
Clinic of Chest Diseases, Sultan Abdülhamid Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
New asthma therapies such as omalizumab, mepolizumab and reslizumab are used according to the inflammatory phenotype, but there are many patients with asthma which are not suitable for these therapies or do not improve with these therapies. Bronchial thermoplasty (BT) was approved by FDA for the treatmet of adults with severe asthma and uncontrolled symptoms despite treatment with inhaler corticosteroids (ICS) and long-acting bronchodilators in 2010. BT is a minimally invasive bronhoscopic intervention based on radiofrequency energy delivery to the larger airways to reduce excessive airway smooth muscle mass.
View Article and Find Full Text PDFRecent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Expert Rev Respir Med
November 2018
a School of Medicine, Medical Sciences and Nutrition , Institute of Medical Sciences, University of Aberdeen, Aberdeen , UK.
Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life and health-care cost implications. Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5, and IL-13 have considerable potential as effective treatments for severe asthma.
View Article and Find Full Text PDFRecent advances in eosinophilic esophagitis.
F1000Res
September 2017
Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati OH, 45529, USA.
Eosinophilic esophagitis is a chronic, antigen-driven, eosinophil-predominant inflammatory disease of the esophagus and affects both children and adults. Cutting-edge technologies, such as genome-wide association studies, have advanced our understanding of the disease pathogenesis at a remarkable rate. Recent insights from genetic and mechanistic studies have concluded that a complex interplay between genetic and environmental risk factors, allergic sensitization, and esophageal-specific pathways leads to disease pathogenesis.
View Article and Find Full Text PDFThe past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.
J Asthma Allergy
November 2015
Department of Pediatrics, Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA ; Department of Internal Medicine, Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Asthma is a heterogeneous syndrome that might be better described as a constellation of phenotypes or endotypes, each with distinct cellular and molecular mechanisms, rather than as a singular disease. One of these phenotypes is eosinophilic asthma. As the development of eosinophilic inflammation is categorically dependent on the biological activity of Interleukin (IL)-5, IL-5 antagonism became an obvious target for therapy in this phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!